Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patient Engagement Needs 'Regulatory Guardrails' To Encourage Firms, Advocates Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Guidance development initiative led by National Health Council and Genetic Alliance will propose to FDA ways to de-risk industry efforts to get patients involved in drug development process.

Advertisement

Related Content

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up

Topics

Advertisement
UsernamePublicRestriction

Register

PS078940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel